Through this acquisition, ICL will gain Lavie Bio’s core team, microbial bank, and key technology assets, further strengthening our biological portfolio and expanding our capabilities in sustainable farming technologies.
Lavie Bio, based in Israel, is recognized for its cutting-edge biostimulants and biopesticides. This acquisition builds on more than two years of collaboration between ICL and Lavie Bio, particularly in developing innovative biostimulant solutions for row crops. By combining Lavie Bio’s advanced technology with ICL’s R&D expertise, we will enhance our position in the biologicals sector and bring more sustainable solutions to farmers worldwide.
The Lavie Bio team will continue to lead their operations and drive research programs dedicated to ICL’s global needs. They will be fully integrated into the Growing Solutions Global R&D organization, reporting to Dr. Elinor Erez, VP R&D.
This acquisition reflects our commitment to expanding our biological portfolio, driving agricultural innovation, and supporting sustainable farming practices. Together, we are shaping a more sustainable future for agriculture.